135 related articles for article (PubMed ID: 20717700)
1. How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives.
Gür Ali O; Topaler B
Eur J Health Econ; 2011 Dec; 12(6):553-62. PubMed ID: 20717700
[TBL] [Abstract][Full Text] [Related]
2. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
Murry L; Gerleman B; Urick B; Urmie J
J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
[TBL] [Abstract][Full Text] [Related]
3. The association of insurance type with costs of dispensed drugs.
Mott DA; Kreling DH
Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
[TBL] [Abstract][Full Text] [Related]
4. Prescription drug benefits: cost management issues for Medicare.
Fox PD
Health Care Financ Rev; 2003; 25(2):7-21. PubMed ID: 15124374
[TBL] [Abstract][Full Text] [Related]
5. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.
Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML
Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608
[TBL] [Abstract][Full Text] [Related]
6. Medicaid prescription drug coverage: state efforts to control costs.
Gencarelli DM
NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
[TBL] [Abstract][Full Text] [Related]
7. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
Harris BN; West DS; Johnson J; Hong SH; Stowe CD
J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
[TBL] [Abstract][Full Text] [Related]
8. Effect of a change in third party reimbursement rate on prescription gross margin.
Ganther JM; Kreling DH
J Am Pharm Assoc (Wash); 1999; 39(3):346-52. PubMed ID: 10363461
[TBL] [Abstract][Full Text] [Related]
9. The effects of copayments and generic substitution on the use and costs of prescription drugs.
Smith DG
Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
[TBL] [Abstract][Full Text] [Related]
10. [Medication supply of privately insured patients in 2010].
Wild F
Versicherungsmedizin; 2012 Jun; 64(2):85-6. PubMed ID: 22808648
[No Abstract] [Full Text] [Related]
11. Generic drugs: international trends and policy developments in Australia.
Lofgren H
Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
[TBL] [Abstract][Full Text] [Related]
12. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
13. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
14. Prescription drugs: issues of cost, coverage, and quality.
Copeland C
EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
[TBL] [Abstract][Full Text] [Related]
15. Incentives and pharmaceutical reimbursement reforms in Spain.
Puig-Junoy J
Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
[TBL] [Abstract][Full Text] [Related]
16. Impact of brand drug discount cards on private insurer, government and patient expenditures.
Law MR; Chan FKI; Harrison M; Worthington HC
CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
[TBL] [Abstract][Full Text] [Related]
17. [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].
Gouya G; Reichardt B; Bidner A; Weissenfels R; Wolzt M
Wien Klin Wochenschr; 2008; 120(3-4):89-95. PubMed ID: 18322770
[TBL] [Abstract][Full Text] [Related]
18. Estimating pharmacy level prescription drug acquisition costs for third-party reimbursement.
Kreling DH; Kirk KW
Med Care; 1986 Jul; 24(7):590-600. PubMed ID: 3523065
[TBL] [Abstract][Full Text] [Related]
19. Evaluation on the first 2 years of the positive list system in South Korea.
Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
[TBL] [Abstract][Full Text] [Related]
20. Assessing changes in third-party gross margin for a single community pharmacy.
Urick BY; Urmie JM; Doucette WR; McDonough RP
J Am Pharm Assoc (2003); 2014; 54(1):27-34. PubMed ID: 24362541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
